Review of the Outcome of the Treatment of Rheumatoid
Factor positive (RF+) Rheumatoid Arthritis (RA)
Introduction
Drugs that have been used in the treatment of RF+ RA
Analgesic, antiinflammation : Aspirin, Analgesics, and
NSAIDs
SAARDs : parenteral gold salts, oral gold, penicillamine
DMARDs : hydroxychloroquine, Sulfasalazine, Methotrexate,
Azathioprine, Cyclophosphamide, and Biologic Response
Modifiers
The pyramid and reversed pyramid methods have been used in
the application of these therapeutic agents and failed
dismally. Over five years, complete remission was obtained
in 30% of patients with RA. However, Remission on the
average lasted only from two months to two years.
Immunosuppressants : used in the SBP-6-IMNs i.e.,
intravenous
Cyclophosphamide, 5-Fluorouracil,
Methylprednisolone, and Methotrexate. Oral
Mycophenolate Mofetil, Cyclosporine, and Methotrexate
Biologic Response Modifiers : Etanercept, Infliximab,
Rituximab, Adalimumab, and
Anakinra
Outcome of the treatment of RF+ RA with the combination of
Methotrexate + Biologic Response Modifiers does not achieve
Remission, save improvement of ACR20, ACR50, and ACR70.
The consequences are that myths are entrenched in the
community, medical professionals, and rheumatologists
Myth No. 1
Remission with whatever therapy is impossible
within months
Myth No. 2
Remission by oral drugs is not possible within
months
Myth No. 3
Remission without drug is unheard of.
Myth No. 4
Radiological Remission of RF+ RA is unheard off
Refution of these myths
Myth No. 1
is refuted by the SBP-5-IMNs with Remission
achieved in 2-4 months
Myth No. 2
is refuted by the SBP-5-IMNs with Remission with
oral Drugs (RworalDs)
achieved in 5.5-7.5 months
Myth No. 3
is refuted by the SBP-5-IMNs with Remission
without Drug (RwD) achieved in 3.5 – 4.5 years
Myth No. 4
is refuted by the SBP-5-IMNs with healing of
erosion(s) and termination of progression of baseline
erosions with prevention of new erosion
How are these outcomes achieved? Click
Clinical outcome
271 patients with RF+ RA treated with the SBP-5-IMNs in a 7
years observational study.
40.2% with erosion grade < 2 independent of disease
duration, achieves Remission
without Drug (RwD)
51.3% with erosion grade > 2 independent of disease
duration, achieves Remission with oral Drugs (RworalDs)
1.5% not IMN-naïve patients, achieves improvement ACR70
7.0% are dropouts.
Radiological outcome after 7 years
Progression of baseline erosion(s) terminated and erosion(s)
healed whatever the grades and new erosion(s) prevented.
With the addition of intravenous 5-Fluorouracil (5FU), the
SBP-5-IMNs becomes
SBP-6-IMNs. To suppress flare, the SBP-6-IMNs is more
effective than the
SBP-5-IMNs, because of IMN-naivity of 5FU, but with similar
adverse effects.
RF+ RA Alert :
do not let RF+ RA progress to > grade 2 erosion(s), because
RwD cannot be achieved by the SBP-6-IMNs.
Email This Page
Print
This Page |
|
| |
NEWS & EVENTS
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
16.11.2005
MabThera – a unique approach providing lasting
benefits for patients with rheumatoid arthritis
Comprehensive long-term clinical success achieved in
difficult-to-treat patients following just two
administrations, two weeks apart
›
more
|
|
 |
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.09.2005
Roche files first rheumatoid arthritis indication for
MabThera in Europe
MabThera: a medicine used to treat non-Hodgkin's
lymphoma
MabThera delivers significant and sustained relief from
symptoms in patients with difficult-to-treat rheumatoid
arthritis.
›
more
|
|
|
|
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.04.2005
MabThera significantly improves symptoms in patients
with rheumatoid arthritis who inadequately responded to
anti-TNFα therapies
Third large randomised trial to evaluate efficacy and
safety of MabThera in RA
Roche, Genentech and Biogen Idec announced today that
REFLEX1, a pivotal Phase III study of MabThera (rituximab), successfully met its
primary endpoint in the group of patients with the most difficult-to-treat
rheumatoid arthritis (RA).
›
more
|
|
 |
Download Instruction
For Internet Explorer :
Right click at "download" text link and choose
Save Target As |
Legal Disclamer
|
Legal Disclaimer
Copyright
©WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune
Diseases.
This Web site was developed in 2005 as a service provided by the
WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune
Diseases. This Web site provides selected information available
about lupus and arthritis. It is important that public see a
healthcare professional for detailed information about medical
conditions and treatment. This information is not intended to be a
substitute for the advice of a healthcare professional, or a
recommendation for any particular treatment plan. The WHO-ILAR
COPCORD Stage II Education on Treatment of the Autoimmune Diseases
has made and will continue to make efforts to include accurate and
up-to-date information on this Web site.
If you have any
questions, please contact us:
Webmaster
Phone: 62-24-8447-345
Fax: 62-24-8310-028
admin@LupusArthritisIndonesia.org
|
|
Bahasa
